QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
Log in
NASDAQ:NXTC

NextCure Competitors

$11.60
+0.12 (+1.05 %)
(As of 03/2/2021 03:56 PM ET)
Add
Compare
Today's Range
$11.36
Now: $11.60
$11.69
50-Day Range
$11.33
MA: $12.62
$13.88
52-Week Range
$7.91
Now: $11.60
$45.15
Volume3,050 shs
Average Volume262,439 shs
Market Capitalization$319.61 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.4

Competitors

NextCure (NASDAQ:NXTC) Vs. PLRX, KROS, RPTX, CDMO, TRIL, and OMER

Should you be buying NXTC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to NextCure, including Pliant Therapeutics (PLRX), Keros Therapeutics (KROS), Repare Therapeutics (RPTX), Avid Bioservices (CDMO), Trillium Therapeutics (TRIL), and Omeros (OMER).

Pliant Therapeutics (NASDAQ:PLRX) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pliant Therapeutics and NextCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pliant Therapeutics00403.00
NextCure14302.25

Pliant Therapeutics currently has a consensus target price of $43.3333, suggesting a potential upside of 17.05%. NextCure has a consensus target price of $23.3333, suggesting a potential upside of 103.61%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than Pliant Therapeutics.

Profitability

This table compares Pliant Therapeutics and NextCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pliant Therapeutics20.83%16.55%8.33%
NextCureN/A-10.00%-9.51%

Valuation & Earnings

This table compares Pliant Therapeutics and NextCure's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$57.05 million23.00$-630,000.00N/AN/A
NextCure$6.35 million50.33$-33,740,000.00($2.15)-5.40

Pliant Therapeutics has higher revenue and earnings than NextCure.

Institutional & Insider Ownership

79.5% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 66.3% of NextCure shares are held by institutional investors. 9.1% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Pliant Therapeutics beats NextCure on 8 of the 11 factors compared between the two stocks.

NextCure (NASDAQ:NXTC) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for NextCure and Keros Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NextCure14302.25
Keros Therapeutics00403.00

NextCure currently has a consensus target price of $23.3333, suggesting a potential upside of 103.61%. Keros Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 34.37%. Given NextCure's higher possible upside, research analysts plainly believe NextCure is more favorable than Keros Therapeutics.

Profitability

This table compares NextCure and Keros Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NextCureN/A-10.00%-9.51%
Keros TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares NextCure and Keros Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCure$6.35 million50.33$-33,740,000.00($2.15)-5.40
Keros TherapeuticsN/AN/AN/AN/AN/A

Keros Therapeutics has lower revenue, but higher earnings than NextCure.

Institutional and Insider Ownership

66.3% of NextCure shares are held by institutional investors. Comparatively, 58.4% of Keros Therapeutics shares are held by institutional investors. 9.1% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NextCure (NASDAQ:NXTC) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for NextCure and Repare Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NextCure14302.25
Repare Therapeutics01513.00

NextCure currently has a consensus target price of $23.3333, suggesting a potential upside of 103.61%. Repare Therapeutics has a consensus target price of $39.40, suggesting a potential upside of 17.93%. Given NextCure's higher possible upside, research analysts plainly believe NextCure is more favorable than Repare Therapeutics.

Profitability

This table compares NextCure and Repare Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NextCureN/A-10.00%-9.51%
Repare TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares NextCure and Repare Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCure$6.35 million50.33$-33,740,000.00($2.15)-5.40
Repare TherapeuticsN/AN/AN/AN/AN/A

Repare Therapeutics has lower revenue, but higher earnings than NextCure.

Institutional and Insider Ownership

66.3% of NextCure shares are held by institutional investors. Comparatively, 64.8% of Repare Therapeutics shares are held by institutional investors. 9.1% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Repare Therapeutics beats NextCure on 5 of the 9 factors compared between the two stocks.

NextCure (NASDAQ:NXTC) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Institutional and Insider Ownership

66.3% of NextCure shares are held by institutional investors. Comparatively, 58.2% of Avid Bioservices shares are held by institutional investors. 9.1% of NextCure shares are held by insiders. Comparatively, 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares NextCure and Avid Bioservices' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCure$6.35 million50.33$-33,740,000.00($2.15)-5.40
Avid Bioservices$59.70 million20.61$-10,470,000.00($0.27)-80.33

Avid Bioservices has higher revenue and earnings than NextCure. Avid Bioservices is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NextCure and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NextCureN/A-10.00%-9.51%
Avid Bioservices0.20%0.31%0.13%

Risk & Volatility

NextCure has a beta of -0.4, meaning that its stock price is 140% less volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for NextCure and Avid Bioservices, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NextCure14302.25
Avid Bioservices00203.00

NextCure currently has a consensus target price of $23.3333, suggesting a potential upside of 103.61%. Avid Bioservices has a consensus target price of $15.50, suggesting a potential downside of 27.26%. Given NextCure's higher possible upside, research analysts plainly believe NextCure is more favorable than Avid Bioservices.

Summary

Avid Bioservices beats NextCure on 8 of the 14 factors compared between the two stocks.

NextCure (NASDAQ:NXTC) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Institutional and Insider Ownership

66.3% of NextCure shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. 9.1% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares NextCure and Trillium Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCure$6.35 million50.33$-33,740,000.00($2.15)-5.40
Trillium Therapeutics$120,000.009,160.41$-41,620,000.00($1.38)-7.74

NextCure has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NextCure and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NextCureN/A-10.00%-9.51%
Trillium TherapeuticsN/A-70.00%-28.84%

Risk and Volatility

NextCure has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NextCure and Trillium Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NextCure14302.25
Trillium Therapeutics01402.80

NextCure presently has a consensus price target of $23.3333, suggesting a potential upside of 103.61%. Trillium Therapeutics has a consensus price target of $21.25, suggesting a potential upside of 93.53%. Given NextCure's higher possible upside, equities research analysts clearly believe NextCure is more favorable than Trillium Therapeutics.

Summary

Trillium Therapeutics beats NextCure on 7 of the 13 factors compared between the two stocks.

NextCure (NASDAQ:NXTC) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Institutional and Insider Ownership

66.3% of NextCure shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 9.1% of NextCure shares are held by company insiders. Comparatively, 11.3% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares NextCure and Omeros' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCure$6.35 million50.33$-33,740,000.00($2.15)-5.40
Omeros$111.81 million11.15$-84,490,000.00($0.96)-21.06

NextCure has higher earnings, but lower revenue than Omeros. Omeros is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NextCure and Omeros' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NextCureN/A-10.00%-9.51%
Omeros-134.59%N/A-59.49%

Risk and Volatility

NextCure has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NextCure and Omeros, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NextCure14302.25
Omeros02402.67

NextCure presently has a consensus price target of $23.3333, suggesting a potential upside of 103.61%. Omeros has a consensus price target of $23.40, suggesting a potential upside of 12.88%. Given NextCure's higher possible upside, equities research analysts clearly believe NextCure is more favorable than Omeros.

Summary

Omeros beats NextCure on 8 of the 14 factors compared between the two stocks.


NextCure Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PLRX
Pliant Therapeutics
1.7$36.99+4.1%$1.26 billion$57.05 million0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$57.90+6.6%$1.25 billionN/A0.00News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.25+1.1%$1.24 billionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Avid Bioservices logo
CDMO
Avid Bioservices
1.4$21.69+0.4%$1.23 billion$59.70 million-216.90Upcoming Earnings
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.68+9.5%$1.20 billion$120,000.00-3.96Upcoming Earnings
Gap Down
Omeros logo
OMER
Omeros
1.2$20.22+4.0%$1.20 billion$111.81 million-8.50Earnings Announcement
News Coverage
Gap Down
Zogenix logo
ZGNX
Zogenix
1.7$20.49+2.2%$1.17 billion$3.65 million-2.15Earnings Announcement
Innoviva logo
INVA
Innoviva
1.4$11.24+1.4%$1.16 billion$261.02 million5.73News Coverage
Annexon logo
ANNX
Annexon
1.7$30.77+2.8%$1.14 billionN/A0.00Upcoming Earnings
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.1$5.10+3.1%$1.13 billion$150,000.00-7.29Earnings Announcement
Analyst Downgrade
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.41+5.1%$1.12 billion$73.41 million-3.89Analyst Report
News Coverage
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.5$34.31+4.0%$1.10 billionN/A0.00Upcoming Earnings
News Coverage
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.5$30.04+1.8%$1.06 billionN/A-13.84
Veru logo
VERU
Veru
1.4$14.02+2.8%$1.04 billion$42.59 million-50.07Increase in Short Interest
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$23.20+3.7%$1.03 billion$4.23 million-17.19Earnings Announcement
Increase in Short Interest
Analyst Revision
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.01+4.1%$1.03 billion$227.19 million50.03
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$13.22+4.0%$1.03 billion$40.89 million-4.56
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.52+9.4%$1.02 billion$230,000.00-13.73Upcoming Earnings
News Coverage
Gap Down
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.91+0.4%$1.00 billion$122.47 million-27.42
Epizyme logo
EPZM
Epizyme
1.7$9.57+2.2%$995.46 million$23.80 million-4.29
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$23.09+4.6%$986.99 million$1.52 million-12.28Upcoming Earnings
News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.69+2.4%$980.54 million$35.22 million-6.34Earnings Announcement
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.43+1.5%$967.99 millionN/A-8.08Earnings Announcement
Analyst Revision
Gap Down
Humanigen logo
HGEN
Humanigen
1.7$17.70+4.5%$954.40 millionN/A0.00Upcoming Earnings
Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$18.89+0.1%$942.32 million$19.89 million-8.91Earnings Announcement
MannKind logo
MNKD
MannKind
1.4$3.79+5.8%$932.73 million$63.04 million-18.05
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$22.18+2.7%$921.52 million$800.40 million20.92
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.47+1.7%$921.00 million$322.07 million-7.11News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.5$22.33+4.9%$891.23 million$14.87 million-8.33Upcoming Earnings
Radius Health logo
RDUS
Radius Health
1.3$18.73+1.2%$882.53 million$173.32 million-7.68Earnings Announcement
Analyst Report
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.36+7.7%$876.23 million$2.22 million-19.76Upcoming Earnings
Analyst Revision
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.1$27.31+1.3%$864.13 millionN/A-25.29Increase in Short Interest
Prothena logo
PRTA
Prothena
2.1$21.79+1.4%$857.90 million$810,000.00-8.51Analyst Report
Kadmon logo
KDMN
Kadmon
2.0$4.72+4.9%$848.99 million$5.09 million-7.87Upcoming Earnings
Gap Up
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.39+0.5%$830.37 million$322.36 million124.21
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.84+0.7%$804.87 millionN/A0.00Upcoming Earnings
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.88+2.3%$796.93 million$148.36 million-7.24
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.6$22.45+2.1%$792.97 million$296.70 million45.82Earnings Announcement
AnaptysBio logo
ANAB
AnaptysBio
1.1$27.67+1.4%$767.11 million$8 million-10.21Earnings Announcement
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.35+2.8%$755.35 million$59.29 million-29.00
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.90+0.4%$754.72 millionN/A-2.78Earnings Announcement
Analyst Revision
News Coverage
Merus logo
MRUS
Merus
1.4$23.81+0.1%$753.10 million$31.13 million-7.76News Coverage
Gap Up
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$19.15+1.0%$746.99 millionN/A-4.89Earnings Announcement
OrganiGram logo
OGI
OrganiGram
1.2$3.19+1.3%$731.65 million$64.61 million-4.69Increase in Short Interest
Provention Bio logo
PRVB
Provention Bio
1.4$12.34+4.3%$727.00 millionN/A-8.28Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$17.30+0.4%$726.38 million$17.26 million-4.81Upcoming Earnings
News Coverage
Akouos logo
AKUS
Akouos
1.7$21.11+0.3%$723.42 millionN/A0.00Upcoming Earnings
Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.73+0.2%$715.27 million$252 million-2.22Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$36.01+3.4%$710.43 million$9.64 million-5.86Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$29.96+2.8%$698.22 million$19.56 million-21.55Decrease in Short Interest
Gap Down
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.